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Abstract
Background: The CCAAT/enhancer-binding protein β (C/EBPβ) is a transcription factor implicated in the control of
proliferation, differentiation, and inflammatory processes mainly in adipose tissue and liver; although more recent
results have revealed an important role for this transcription factor in the brain. Previous studies from our laboratory
indicated that CCAAT/enhancer-binding protein β is implicated in inflammatory process and brain injury, since mice
lacking this gene were less susceptible to kainic acid-induced injury. More recently, we have shown that the
complement component 3 gene (C3) is a downstream target of CCAAT/enhancer-binding protein β and it could be
a mediator of the proinflammatory effects of this transcription factor in neural cells.
Methods: Adult male Wistar rats (8–12 weeks old) were used throughout the study. C/EBPβ+/+ and C/EBPβ–/– mice
were generated from heterozygous breeding pairs. Animals were injected or not with kainic acid, brains removed,
and brain slices containing the hippocampus analyzed for the expression of both CCAAT/enhancer-binding protein
β and C3.
Results: In the present work, we have further extended these studies and show that CCAAT/enhancer-binding
protein β and C3 co-express in the CA1 and CA3 regions of the hippocampus after an excitotoxic injury. Studies
using CCAAT/enhancer-binding protein β knockout mice demonstrate a marked reduction in C3 expression after
kainic acid injection in these animals, suggesting that indeed this protein is regulated by C/EBPβ in the
hippocampus in vivo.
Conclusions: Altogether these results suggest that CCAAT/enhancer-binding protein β could regulate brain
disorders, in which excitotoxic and inflammatory processes are involved, at least in part through the direct
regulation of C3.
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Background
CCAAT/enhancer-binding protein β (C/EBPβ) is a
member of a family of transcription factors whose
members contain a basic leucine-zipper domain for
DNA binding and dimerization [1, 2]. C/EBPβ exists
in three isoforms generated from a single messenger
RNA (mRNA) due to alternative translation initiation
sites [3, 4]. C/EBPβ is expressed in numerous tissues,
including liver, adipose tissue, kidney, lung, ovary,
mammary gland, and hematopoietic tissues, and regu-
lates a variety of biological processes, including me-
tabolism, proliferation and differentiation (depending
on the cell context), and immune response [1, 5–8].
In the nervous system, C/EBPβ is essential for regulating
numerous processes such as synaptic plasticity and long-
term memory [9, 10], neuronal differentiation [11, 12],
neuroinflammation and excitotoxicity [13–16], and hippo-
campal neurogenesis [17]. Also, due to its relevance in the
* Correspondence: piedras3@med.ucm.es; aperez@iib.uam.es
†Equal contributors
2Centro de Investigación Biomédica en Red sobre Enfermedades
Neurodegenerativas (CIBERNED), 28031 Madrid, Spain
1Instituto de Investigaciones Biomédicas, (CSIC-UAM), Arturo Duperier, 4,
28029 Madrid, Spain
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Hernandez-Encinas et al. Journal of Neuroinflammation  (2016) 13:276 
DOI 10.1186/s12974-016-0742-0
indicated cellular processes, C/EBPβ is also involved
in the pathogenesis of different diseases, e.g., cancer,
hyper-inflammatory processes, and bacterial infections
[1, 18, 19]. As it happens in normal physiological
conditions, this regulation takes place via the regulation of
many genes involved in these processes [15–17, 20, 21].
The complement pathway is an essential regulator of
the immune response, including chemotaxis, phago-
cytosis, cell adhesion, and B and T cell differentiation
[22, 23], and it is a very important line of defense
against infections through the elimination of invading
pathogens and regulation of the adaptive immune
response [24, 25]. Regarding the central nervous sys-
tem, several studies have shown that the complement
system plays also important roles in the central ner-
vous system that extend far beyond host defense and
inflammatory processes [26–32]. Specifically, comple-
ment component 3 (C3), a central component of the
complement cascade, is a critical mediator of synaptic re-
finement and plasticity [31, 33] and localizes at synapsis
where it mediates its pruning during development [31, 34],
normal aging [35], and neurodegeneration [36, 37]. In fact,
mice deficient in C3 exhibit deficits in synaptic remodeling,
increased synaptic connectivity, and enhanced epileptiform
activity due to failed synaptic pruning [38]. It has been also
shown that C3 regulates hippocampal neurogenesis in
adult mammalian brain [39] and C3-deficient mice present
impaired neurogenesis following cerebral ischemia [40, 41].
Besides its role in normal physiological conditions,
also uncontrolled complement activation in the brain
has been associated with various neurodegenerative
disorders, including Alzheimer’s disease, Parkinson’s
disease, Huntington’ disease, dementia, and multiple
sclerosis [30, 42–50]. Increased levels of C3 have been
found in the cerebrospinal fluid (CSF) of patients with
Parkinson’s and Alzheimer’s diseases, and these levels
augment with the progression of the disease [49].
Zanjani et al. showed that C3 localized surrounding β-
amyloid plaques in early stages of Alzheimer’s disease,
when an important loss of synapsis takes place [51], and
other authors have demonstrated a modulatory role of C3
on amyloid pathology in animal models of Alzheimer’s
disease [52, 53]. However, little is known about the mech-
anisms regulating C3 expression and its influence on
neuronal function and dysfunction in the adult brain.
Taking into account the previous results from our
laboratory showing a direct regulation of C3 by C/EBPβ
in neural cells [54], here we examined the possible regu-
lation by C/EBPβ of C3 expression in the hippocampus
in an animal model of excitotoxicity. For this purpose,
we have analyzed the expression of both C/EBPβ and C3
after an excitotoxic injury induced by kainic acid (KA)
injection in the hippocampus of rodents (rats and mice).
Our results reveal a strong induction of C/EBPβ and C3
in the CA1 and CA3 regions of the hippocampus follow-
ing kainic acid injection. We also show a pronounced
reduction of C3 levels in C/EBPβ knockout mice, which
have reduced neurotoxicity [16]. These data point to a
role for C3 as a possible mediator of the effects of C/
EBPβ in inflammatory and excitotoxic processes in vivo.
Methods
Animals
Adult male Wistar rats (8–12 weeks old) were used
throughout the study. C/EBPβ+/+ and C/EBPβ–/– mice
were generated from heterozygous breeding pairs,
kindly provided by C. M. Croniger and R. W. Hanson
(Case Western Reserve University, Cleveland, OH) [55].
Genotypes were identified using genomic PCR, with DNA
prepared from tail using the REDExtract-N-AmpTM tis-
sue PCR kit (XNAT kit, Sigma, St Louis, MO). Five ani-
mals from each experimental group were analyzed. All
procedures with animals were specifically approved by the
“Ethics Committee for Animal Experimentation” of the
Instituto de Investigaciones Biomédicas and carried out in
accordance with the European Communities Council, dir-
ective 2010/63/EEC and National regulations, normative
53/2013. Special care was taken to minimize pain or dis-
comfort of animals.
Kainic acid injection in vivo
Adult male rats, C/EBPβ+/+ and C/EBPβ–/– mice, were
anesthetized by intraperitoneal injection of ketamine
(60 mg/kg) and medetomidine (0.125 mg/kg) and posi-
tioned in a stereotaxic apparatus (Kopf Instruments,
CA). Kainic acid (KA) (0.25 μg in 2.50 μl PBS) was deliv-
ered unilaterally into the left hippocampus. Flow rate
(1 μl/min) was kept constant with a motorized syringe
pump (BASi), and the needle was kept in place for
2 min post-injection before being slowly withdrawn.
Control animals of the same age were injected with ve-
hicle. Animals were then housed individually to recover
and sacrificed 72 h after lesioning with KA.
Quantitative real-time-PCR
Total rat or mouse hippocampal RNA samples (2 μg)
were used for the synthesis of complementary DNA
(cDNA) by reverse transcription using the Reverse
Transcription System (Promega, Madison, WI, USA)
with a pd(N)6 random hexamer. Real-time PCR was per-
formed in an ABI Prism machine using the SYBR Green
PCR Master Mix (Applied Biosystems, Warrington, UK)
and 300 nM concentrations of specific primer. The
primers used for the determination of the concentration
of both rat and mouse C3 mRNA were 5′-ACC TTA
CCT CGG CAA GTT TCT-3′(forward sequence) and
5′-TTG TAG AGC TGC TGG TCA GG-3′(reverse se-
quence), which synthesized a fragment of 140 bp. In all
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runs, melting curves were performed to ensure that only
one DNA fragment was amplified. Cycle threshold
(dilution 1:10) was around 25. Amplification of the 18S
rRNA was used for normalization of cDNA loading in
the PCR as previously described [56]. The relative
mRNA content was determined with the 2-ΔΔCt
method [57].
Immunohistochemistry
Animals previously anesthetized were perfused trans-
cardially with 4 % paraformaldehyde, and the brains
were removed, postfixed, and processed for immuno-
histochemistry using the diaminobenzidine (DAB) method
or double-immunofluorescence analysis, as previously
described [58]. The following primary antibodies were
used: rabbit polyclonal anti-C3 (Abcam, Cambridge,
UK), mouse monoclonal anti-C/EBPβ (Abcam, Cambridge,
UK), rabbit polyclonal anti-NeuN (Merck-Millipore,
Darmstadt, Alemania), rabbit polyclonal anti-IL-1β
(Abcam), rat monoclonal anti-CD11b (clon OX42,
Serotec, Oxford, UK), and rabbit polyclonal anti-glial fi-
brillary acidic protein (GFAP, Dako, Glostrup, Denmark)
for immunodetection of astrocytes. For immunofluores-
cence analysis to detect C3, a secondary Alexa-Fluor488
goat anti-rabbit was used in combination with Texas Red
Lycopersicon esculentum (tomato lectin; Vector Labs
USA, emission at 546) to label microglial cells or
Neurotrace fluorescent Nissl stain (emission at 546;
Molecular Probes, Madrid, Spain) to stain neurons.
The slides processed with DAB were examined with a
Nikon Eclipse 80i (Düsseldorf, Germany) microscope,
equipped with a Nikon DS-Fi1 digital camera. For
double immunofluorescence, a LSM710 laser scanning
spectral confocal microscope (Zeiss) was used. Confocal
microscope settings were adjusted to produce the
optimum signal-to-noise ratio. Orthogonal image acquisi-
tion was performed as previously described [59]. Briefly,
sections containing the CA3 region of the hippocampus
were used for the analysis. Confocal acquisitions with
orthogonal projections show co-localization of C3/
neurotrace, C3/GFAP, and C3/tomato lectin, over the ex-
tent of the cell in consecutive 0.5- or 2-μm z-stacks.
A differential interference contrast (DIC) microscope
was used to identify the morphology of cells. The images
were acquired using a Nikon 90i microscope equipped
with a Plan Apo 100× Ph3 DM objective and connected
to Nis-Elements BR software.
Fluoro-Jade staining
To evaluate neuronal degeneration, Fluoro-Jade B
staining was used [60]. Briefly, sections mounted in
gelatin-coated slides were immersed in 100 % alcohol,
followed by 70 % alcohol and distilled water contain-
ing permanganate. Slides were then incubated with
0.001 Fluoro-Jade B dye (Chemicon, Temecula, USA)
for 30 min at room temperature. After staining, sec-
tions were washed with distilled water and mounted
with DePeX (Serva).
TUNEL staining
Frozen hippocampal sections were mounted in gelatin-
coated slides. The TUNEL protocol was performed using
the In Situ Cell Death Detection Kit, POD (Roche
Diagnostics, Indianapolis, USA), following the manufac-
turer’s instructions. Slides were mounted with Vectashield
(Vector Laboratories), and TUNEL staining was visualized
and imaged using a Nikon Eclipse 80i (Düsseldorf,
Germany) microscope, equipped with a Nikon DS-Fi1
digital camera.
Results
Kainic acid induced neurodegeneration in the CA3 region
of the hippocampus in rats and mice
First, we validated our models of excitotoxicity by analyz-
ing the damaging effect of KA in the CA3 subfield, which
is the most sensitive area of the hippocampus to this exci-
totoxin. As expected, we found a dramatic increase in the
number of degenerating neurons stained with Fluoro-Jade
B (Fig. 1a) in rats and mice injected with KA, which was
more noticeable in the pyramidal cells of this area. We
also found that this cell death occurs via apoptosis since a
significant increase in the number of TUNEL+ cells
(Fig. 1b) was also observed, which was not detected in C/
EBPβ-deficient mice (Fig. 1b).
KA induces the expression of C/EBPβ and C3 genes in the
hippocampus of adult rats
We next studied the content of C/EBPβ and C3 pro-
teins, by immunohistochemistry analysis, in consecutive
slices of the hippocampus of adult rats after KA injury.
As shown in Fig. 2a, C/EBPβ and C3 proteins are barely
detectable in the hippocampus of control animals. In
contrast, after KA injection, a dramatic increase of both
proteins was observed, which was most prominent in
the CA3 subfield of the hippocampus (Fig. 2a). No
expression of either C/EBPβ or C3 was detected in other
hippocampal areas. It is known that the injection of KA
can cause the rupture of the blood brain barrier (BBB)
allowing the entry of plasmatic proteins into the brain.
Therefore, we next analyzed whether the C3 protein
found in the CA3 region after KA injection comes from
outside the central nervous system or is due to a local
synthesis in the hippocampus. To this end, we studied
the hippocampal amount of C3 mRNA by quantitative
PCR. Figure 2b shows that in fact C3 mRNA was also
increased after KA injection indicating that the observed
increase in C3 protein is caused, at least in part, by an
increase in the production of C3 gene in brain cells.
Hernandez-Encinas et al. Journal of Neuroinflammation  (2016) 13:276 Page 3 of 12
Fig. 1 Excitotoxic brain injury induced by KA injection in the hippocampus. Animals were injected in the right hemisphere with KA and sacrificed
72 h post-injection. a Representative images of Fluoro-Jade B staining in the CA3 region of the hippocampus. Scale bars, 200 μm (rat) and
250 μm (mouse). Inset scale bars, 50 μm (rat) and 25 μm (mouse). b Representative images of TUNEL staining in the CA3 region of the
hippocampus. Scale bar, 50 μm. Inset scale bar, 25 μm
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KA induces C3 expression in neurons and glial cells in the
hippocampus of adult rats
Next we analyzed the cell types responsible for the KA-
induced increase in C3 observed in the rat hippocampus.
For that purpose, we performed double immunostaining
in the CA3 region of the rat hippocampus, the region
were the induction of C3 is most prominent. As shown
in Fig. 3a, double labeling with a C3-specific antibody
and neurotrace, a specific marker for neurons, clearly
indicates the presence of C3 protein inside the neurons
and also in the surrounding area 72 h after KA injection.
Given the massive neuronal cell death that takes place in
this region of the hippocampus, these observations
suggest that C3 may be localized in those neurons that
are already degenerating.
After brain injury, there is an increase in the num-
ber of reactive glial cells, both active astrocytes and
microglial cells as labeled with a GFAP-specific anti-
body and tomato lectin, respectively. As expected,
after KA injection, we observed an increase of both
types of reactive glial cells. The presence of C3 pro-
tein was detected in both microglial cells and astro-
cytes, as shown in Fig. 3b, c, respectively. In addition,
double-immunofluorescence analysis shows that the
increase in C/EBPβ levels observed in wild type ani-
mals takes place in neurons (Fig. 3d).
Interestingly an increase in C3 labeling was clearly ob-
served surrounding the microvasculature of the KA-
injected hippocampus (Additional file 1) suggesting an im-
plication of this protein in angiogenesis. Additionally, in
this Figure, after double staining with a C3-specific anti-
body and tomato lectin, we show images of C3 localization
near microglial cells suggesting also the opsonization and
phagocytosis functions of C3 and microglial cells.
KA induces the expression of C/EBPβ and C3 genes in the
hippocampus of adult mice
Next, we analyzed whether the coexpression of C3 and
C/EBPβ in the same areas of the hippocampus also took
place in mice. We find also a dramatic increase in the
amount of C/EBPβ and C3 proteins in the hippocampus
after KA injection. As shown in Fig. 4a, both proteins
are almost undetectable in controls in the diverse
regions of the hippocampus analyzed. A clear increase is
observed after KA injection; however, and in contrast
with rats, we could detect C/EBPβ and C3 proteins in
three different regions of the hippocampus, CA1, CA3,
and dentate gyrus (DG). Figure 4b shows differential
Fig. 2 Induction of C/EBPβ and C3 expression after KA injection in adult rats. Animals were injected in the right hemisphere with KA and
sacrificed 72 h post-injection. a Immunohistochemical analysis of coronal brain sections using specific anti-C/EBPβ and anti-C3 antibodies,
showing the CA3 field of the hippocampus. Scale bar, 100 μm. Inset scale bar, 25 μm. b RT-PCR analysis of C3 mRNA content in the hippocampus
of adult rats treated or not with KA. The graphic shows the mean ± SD of three different experiments. *P < 0.05
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interference contrast (DIC) images of C/EBPβ and C3 to
show the whole cell. A combination of DAB (C3) and
fluorescence (C/EBPβ) staining shows that the increase
of both proteins occurs in the same cells (Fig. 4c).
The absence of C/EBPβ blocks the induction of C3 by KA
in the mouse hippocampus
In order to determine the causative implication of C/
EBPβ in the KA-induced expression of the C3 gene, we
analyzed the effect of KA injection in the hippocampal
expression of C3 gene in C/EBPβ−/− mice. As can be
observed in Fig. 5a, C3 protein levels were clearly
increased relative to vehicle-injected controls in the
hippocampus 72 h following KA injection of C/EBPβ+/+
animals. On the contrary, no increase in C3 was ob-
served in the hippocampus of C/EBPβ−/− mice. These
data further support the notion that the transcription
factor C/EBPβ is a major regulator of C3 gene expres-
sion in the brain [54]. Furthermore, our results show
that mice lacking C/EBPβ do not present an increase in
C3 mRNA levels after the lesion (Fig. 5b), further indi-
cating that indeed C/EBPβ is essential to induce C3
Fig. 3 Induction of C3 expression after KA injection in neurons and glial cells in the CA3 region of the hippocampus of adult rats. a Double
fluorescent immunohistochemistry showing C3 expression (green) near hippocampal neurons labeled with neurotrace (red). b Representative
images showing the expression of C3 (green) and microglial cells stained with tomato lectin (red). c Immunohistochemistry performed using a
fluorescent antibody against GFAP (green) together with a DAB-stained anti-C3. Scale bar, 20 μm. Inset scale bar, 10 μm. DAPI was used as a
nuclear marker. All images represent the maximum intensity projection, and orthogonal views are also shown, generated by projecting z-series in
the x- and y-planes. d Double-immunofluorescence images showing C/EBPβ expression after KA injection in neuronal cells (NeuN-positive cells).
Scale bar, 50 μm
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expression in the hippocampus and also suggesting a
local production of C3.
One of the events that takes place in the hippocampus
after KA injury is the activation of microglial cells and
the liberation of proinflammatory cytokines, which is in
part responsible for the neuronal degeneration. Glial
activation (as shown by GFAP- and OX42-positive cells)
and induction of IL1β (a very potent proinflammatory
agent) were clearly observed in the hippocampus of wild
type mice 72 h after KA injection (Fig. 6). This strong
neuroinflammation process was completely absent in the
hippocampus of C/EBPβ−/− mice.
Discussion
In this work, we focused on the analysis of coexpression
of C/EBPβ and C3 in an in vivo model of excitotoxicity.
We chose this model since previous studies from our
laboratory demonstrate an important role of C/EBPβ in
excitotoxic processes [16]. Our results show that the
injection of KA induces the expression of C/EBPβ and
Fig. 4 Induction of C/EBPβ and C3 expression after KA injection in adult mice. Animals were injected in the right hemisphere with KA and sacrificed
72 h post-injection. a Immunohistochemical analysis of coronal brain sections using specific anti-C/EBPβ and anti-C3 antibodies, showing the CA3,
CA1, and DG fields of the hippocampus. Scale bar, 50 μm. Inset scale bar, 25 μm. b Differential interference contrast images of coronal brain sections
using specific anti-C/EBPβ and anti-C3 antibodies, showing the CA3, CA1, and DG fields of the hippocampus. Scale bar, 10 μm. c Representative images
showing coexpression of C3 (DAB staining) and C/EBPβ (fluorescence) in the CA3 region. Scale bar, 20 μm. Inset scale bar, 10 μm
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C3 genes in the hippocampus of mice and rats. We also
show that the induction of both genes occurs in the
same cell and is impaired in cells depleted of C/EBPβ.
These data, together with a previous study from our
laboratory showing a direct regulation of mouse C3 pro-
moter by C/EBPβ in vitro [54], indicate that C3 is a
downstream target of C/EBPβ after a brain injury.
Because C3 functions as a central complement compo-
nent, most probably this gene plays an important role in
the proinflammatory effects of C/EBPβ in the central
nervous system.
The C/EBPβ gene plays an important role in neuroin-
flammation [61]. Its expression and the activity of the
protein are upregulated by brain injury and inflamma-
tory conditions and, additionally, C/EBPβ induces the
expression of genes coding for proinflammatory cyto-
kines [16, 62]. The induction by KA of C/EBPβ expres-
sion in the hippocampus of mice and rats shown in this
Fig. 5 Expression of C3 in C/EBPβ wild type and knockout mice. Mice were injected with KA in the right hemisphere, sacrificed 72 h later.
a Immunohistochemistry analysis of coronal brain sections using an specific anti-C3 antibody showing the CA3, CA1, and DG fields of the
hippocampus. No induction in the expression of C3 was observed in C/EBPβ knockout mice after KA injection, compared with their wild type
littermate controls. Scale bar, 50 μm. Inset scale bar, 25 μm. b RT-PCR analysis of C3 mRNA content in the hippocampus of adult C/EBPβ+/+ and
C/EBPβ−/− mice treated or not with KA. The graphic shows the mean of three different experiments
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work is in agreement with previous data from our la-
boratory showing, in mice injected with KA, an increase
in the nuclear content of C/EBPβ mainly in the granular
neurons of the dentate gyrus, but also in astrocytes and
microglia cells [16]. Here we have extended these results
by showing that C/EBPβ is also clearly induced in the
CA1 and CA3 regions of the mouse hippocampus,
which is in agreement with the described presence of C/
EBPβ transcripts in these subfields of the adult mouse
hippocampus, although at lower levels than in the den-
tate gyrus [63]. In contrast with the mouse, in the rat
hippocampus the induction of C/EBPβ expression by
KA was observed only in the CA3 subfield of the hippo-
campus, indicating a clear difference between both
species. Interestingly, this enhancement in C/EBPβ pro-
tein levels occurs in neurons, as we previously observed
in the dentate gyrus of mice. All these data are consist-
ent with previous work showing the induction of C/
EBPβ gene expression by KA and proinflammatory
agents in primary cultured glial cells [13, 14, 16].
C/EBPβ regulates the expression of various cytokine
and chemokine genes, which play an important role
in the regulation of innate and adaptive immunity
[64–66]. The regulation of many of them is probably
directly dependent of C/EBPβ. Such is the case of the
proinflammatory cytokines IL-1β, IL6, and TNFalpha,
where active C/EBPβ binding sites have been de-
scribed in the corresponding promoters of the human
genes [67, 68]. The results presented in this work
showing a parallel induction of C/EBPβ and C3 genes
by KA and a lack of induction of C3 in C/EBPβ
knockout mice, together with the commented previ-
ous results from our laboratory showing that C/EBPβ
directly regulates the expression of C3 [54], clearly in-
clude C3 gene among those genes directly regulated
by C/EBPβ.
Accumulation of C3 protein after KA injection was
observed in both glial and neuronal cells as shown by
double labeling with a C3-specific antibody and cell
type-specific markers. In the rat CA3 subfield, labeling
with neurotrace, a specific neuronal marker, together
with a C3 antibody, clearly indicates the presence of C3
protein inside the neurons and also in the surrounding
area. Given the massive neuronal cell death that takes
place in this region of the hippocampus, these observa-
tions suggest that C3 may be localized in those neurons
that are already degenerating. In the case of glial cells,
C3 accumulates in activated astrocytes and microglial
cells. When double immunostaining for C3 and C/EBPβ
was performed in the CA3 region of the mouse hippo-
campus after KA injection, both proteins were found in
the same cells (C3 in the cytosol and C/EBPβ in the
nucleus). These results further suggest that C3 expres-
sion could be regulated by C/EBPβ both in glial and
neuronal cells and are consistent with other results
showing that in the brain C3 can be produced by neur-
onal and glial cells [23, 69]. Specifically, in situ
hybridization studies [32, 70–72] have shown that the
C3 component is locally produced in glial cells and neu-
rons and that the presence of C3 is not merely due to
leakage of plasma proteins because of blood brain bar-
rier damage.
Regarding the regulation of C3 gene expression by C/
EBPβ, our results are in agreement with previous work
showing that C/EBPβ plays an important role in the
regulation of C3 expression by IL-1β [73, 74] and also
with data from microarray analysis by our laboratory
showing that the overexpression of C/EBPβ in neuro-
blastoma cells and its absence in the mouse hippocam-
pus correlates, respectively, with an increase and a
decrease in the amount of C3 transcripts [15, 54]. More-
over, the results presented here show that the increase in
C3 mRNA after KA injection observed in control mice
is not detected in C/EBPβ-deficient mice, further sug-
gesting that C/EBPβ is essential to induce C3 expression
in the hippocampus after KA injection.
Consistent with the hypothesis that the C3 gene
could play an important role as mediator of the
Fig. 6 Increased hippocampal inflammation after KA injection in C/
EBPβ wild type mice. Mice were injected with KA in the right
hemisphere, sacrificed 72 h later, and immunohistochemistry analysis
were performed using specific anti-GFAP, anti-OX42, and anti-IL1β
antibodies. No induction of inflammation was observed in C/EBPβ
knockout mice after KA injection, compared with their wild type
littermate controls. Scale bar, 100 μm
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proinflammatory effect of C/EBPβ, some data in the
literature implicate C3 as an active factor in neuronal
damage in experimental models of inflammation [75, 76]
and traumatic brain injury [77, 78]. In this regard, it has
been shown that C3-deficient mice show less neuronal
loss and microglial activation in several models of brain
injury in different brain areas, including the hippocampus
[75, 79–81]. However, the function of the C3 is complex
and a protective effect of C3 has been described in
experimental models of Alzheimer’s disease, probably
as a consequence of favoring the clearance of Aβ
plaque [82, 83].
Excitotoxicity has been implicated as a pathogenic
mechanism associated with different brain disorders, in-
cluding acute brain injury and neurodegenerative dis-
eases, including epilepsy [84, 85]. Glutamate is the major
excitatory neurotransmitter in the central nervous sys-
tem and a primary driver of the excitotoxic process.
Although glutamate plays a central role in excitatory
neurotransmission, alterations in glutamate homeostasis
can have significant repercussions on neurons through
the generation of neurotoxic and excitotoxic cascades.
Particularly sensitive to KA injection are the hippocam-
pal CA1 and CA3 regions, and the hilar neurons of the
dentate gyrus [86]. Glial cells have an important role in
the course of KA-induced hippocampal neurodegenera-
tion. Activated astrocytes and microglial cells proliferate
and increase the expression of genes involved in this
degeneration process.
Regarding epilepsy, our results are in accordance with
previous works showing an implication of the comple-
ment system in epilepsy. Specifically, an increase in C3
expression in the brain of patients with temporal lobe
epilepsy [87, 88] has been shown, which is the common
type in adults and is characterized by neuronal loss and
gliosis in the hippocampus. The current literature dem-
onstrates that injury to the brain results in a temporally
orchestrated genetic response by neurons and glial
cells, which involves signaling pathways that promote
cell death and survival, yet a more complete elucidation
of the exact molecular mechanisms is required. In par-
ticular, determination of the transcription factors in-
volved and the downstream gene effectors they induce
will provide invaluable insight into the neuroprotective
signaling pathways. This will have immense public
health implications, prevent ill health, and reduce the
cost to society. In this regard, our results suggest that
C/EBPβ and C3 might be important molecular new tar-
gets responsible for the neurodegeneration that occurs
after a brain injury. It is important to note that this
work shows that C/EBPβ regulates in vivo the expres-
sion of C3 in the hippocampus after an excitotoxic in-
jury since C/EBPβ knockout mice do not show the
induction of C3 after KA injection.
Conclusions
Collectively, our findings further demonstrate an activa-
tion of the C3 gene in vivo by C/EBPβ and suggest a role
for C3 as a mediator of this transcription factor follow-
ing a brain insult.
Additional file
Additional file 1: Double-immunofluorescence analysis showing C3
expression near microglia and blood vessels 72 h after KA injection in
adult rats. All images represent the maximum intensity projection, and
orthogonal views are also shown, generated by projecting z-series in the
x- and y-planes. Scale bar, 5 μm. (TIF 2327 kb)
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